-
Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking
Thursday, June 28, 2018 - 11:42am | 408Read More...The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday. The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but...
-
Stifel's ASCO Abstract Cheat Sheet
Thursday, May 18, 2017 - 9:57am | 587Read More...Commenting on the abstracts for the annual American Society of Clinical Oncology, or ASCO, meeting released after market close on Wednesday, Stifel gave its overview of the specific abstracts. The ASCO is scheduled to be held June 2–6 this year. Sell-Off In NewLink Genetics Unfounded...
-
BioMarin's Carnage Could Be Buying Opportunity, Says Stifel
Tuesday, February 16, 2016 - 12:06pm | 317Read More...According to a recent research summary from Stifel, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is deserving of an upgrade. Analysts Stephen Willey and Prakhar Verma began, “While acknowledging this isn't the easiest of environments for upgrading stocks, we do believe sector...
